{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:15:31Z","timestamp":1792818931456,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41577-022-00762-9","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T10:03:04Z","timestamp":1659693784000},"page":"639-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":360,"title":["Understanding COVID-19-associated coagulopathy"],"prefix":"10.1038","volume":"22","author":[{"given":"Edward M.","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7700","authenticated-orcid":false,"given":"Nigel","family":"Mackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Q.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa S.","family":"Wolberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent O.","family":"Mosnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-8002","authenticated-orcid":false,"given":"Lisa E.","family":"Gralinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Rondina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin M.","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-1601","authenticated-orcid":false,"given":"Kyung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-1569","authenticated-orcid":false,"given":"James H.","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"762_CR1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/jth.14830","volume":"18","author":"S Cui","year":"2020","unstructured":"Cui, S., Chen, S., Li, X., Liu, S. & Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 18, 1421\u20131424 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"762_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"762_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10478","volume":"3","author":"J Nahum","year":"2020","unstructured":"Nahum, J. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw. Open 3, e2010478 (2020).","journal-title":"JAMA Netw. Open"},{"key":"762_CR5","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","volume":"7","author":"G Goshua","year":"2020","unstructured":"Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 7, e575\u2013e582 (2020).","journal-title":"Lancet Haematol."},{"key":"762_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020191","author":"T Iba","year":"2021","unstructured":"Iba, T., Warkentin, T. E., Thachil, J., Levi, M. & Levy, J. H. Proposal of the definition for COVID-19-associated coagulopathy. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10020191 (2021).","journal-title":"J. Clin. Med."},{"key":"762_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ancard.2020.09.027","volume":"69","author":"A Trimaille","year":"2020","unstructured":"Trimaille, A. & Bonnet, G. [COVID-19 and venous thromboembolism] [French]. Ann. Cardiol. Angeiol. 69, 370\u2013375 (2020).","journal-title":"Ann. Cardiol. Angeiol."},{"key":"762_CR8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.120.048488","volume":"142","author":"L Nicolai","year":"2020","unstructured":"Nicolai, L. et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 142, 1176\u20131189 (2020).","journal-title":"Circulation"},{"key":"762_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fcvm.2020.00151","volume":"7","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. Incidence of venous thromboembolism in hospitalized coronavirus disease 2019 patients: a systematic review and meta-analysis. Front. Cardiovasc. Med. 7, 151 (2020).","journal-title":"Front. Cardiovasc. Med."},{"key":"762_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.120.046702","volume":"142","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 142, 114\u2013128 (2020).","journal-title":"Circulation"},{"key":"762_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M20-2003","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann. Intern. Med. 173, 268\u2013277 (2020).","journal-title":"Ann. Intern. Med."},{"key":"762_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844\u2013847 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR13","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/jmv.26097","volume":"92","author":"N Ali","year":"2020","unstructured":"Ali, N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J. Med. Virol. 92, 2409\u20132411 (2020).","journal-title":"J. Med. Virol."},{"key":"762_CR14","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2021.016","volume":"13","author":"C Agrati","year":"2021","unstructured":"Agrati, C. et al. Elevated P-selectin in severe COVID-19: considerations for therapeutic options. Mediterr. J. Hematol. Infect. Dis. 13, e2021016 (2021).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"762_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507\u2013513 (2020).","journal-title":"Lancet"},{"key":"762_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.2021.17272","volume":"326","author":"JM Connors","year":"2021","unstructured":"Connors, J. M. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA 326, 1703\u20131712 (2021).","journal-title":"JAMA"},{"key":"762_CR17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/ATVBAHA.120.315338","volume":"41","author":"EG Bouck","year":"2021","unstructured":"Bouck, E. G. et al. COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler. Thromb. Vasc. Biol. 41, 401\u2013414 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"762_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12525","volume":"5","author":"RA Campbell","year":"2021","unstructured":"Campbell, R. A. et al. Comparison of the coagulopathies associated with COVID-19 and sepsis. Res. Pract. Thromb. Haemost. 5, e12525 (2021).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"762_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"762_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"762_CR21","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. & Levy, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 135, 2033\u20132040 (2020).","journal-title":"Blood"},{"key":"762_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jth.14849","volume":"18","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. & Levy, J. H. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 18, 1559\u20131561 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34\u201345 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"762_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169\u20131179 (2020).","journal-title":"Blood"},{"key":"762_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141374","author":"P Skendros","year":"2020","unstructured":"Skendros, P. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI141374 (2020).","journal-title":"J. Clin. Invest."},{"key":"762_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073868","author":"J Mandel","year":"2022","unstructured":"Mandel, J., Casari, M., Stepanyan, M., Martyanov, A. & Deppermann, C. Beyond hemostasis: platelet innate immune interactions and thromboinflammation. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23073868 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"762_CR27","doi-asserted-by":"publisher","first-page":"20180080","DOI":"10.1098\/rsfs.2018.0080","volume":"9","author":"SC Purcell","year":"2019","unstructured":"Purcell, S. C. & Godula, K. Synthetic glycoscapes: addressing the structural and functional complexity of the glycocalyx. Interface Focus. 9, 20180080 (2019).","journal-title":"Interface Focus."},{"key":"762_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","volume":"20","author":"LA Teuwen","year":"2020","unstructured":"Teuwen, L. A., Geldhof, V., Pasut, A. & Carmeliet, P. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 20, 389\u2013391 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"762_CR29","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/cvr\/cvaa230","volume":"116","author":"PC Evans","year":"2020","unstructured":"Evans, P. C. et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc. Res. 116, 2177\u20132184 (2020).","journal-title":"Cardiovasc. Res."},{"key":"762_CR30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/ATVBAHA.120.314860","volume":"40","author":"S Nagashima","year":"2020","unstructured":"Nagashima, S. et al. Endothelial dysfunction and thrombosis in patients with COVID-19-brief report. Arterioscler. Thromb. Vasc. Biol. 40, 2404\u20132407 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"762_CR31","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.336","author":"S Renzi","year":"2020","unstructured":"Renzi, S., Landoni, G., Zangrillo, A. & Ciceri, F. MicroCLOTS pathophysiology in COVID 19. Korean J. Intern. Med. https:\/\/doi.org\/10.3904\/kjim.2020.336 (2020).","journal-title":"Korean J. Intern. Med."},{"key":"762_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417\u20131418 (2020).","journal-title":"Lancet"},{"key":"762_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/CIRCULATIONAHA.120.052824","volume":"143","author":"IR McCracken","year":"2021","unstructured":"McCracken, I. R. et al. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 143, 865\u2013868 (2021).","journal-title":"Circulation"},{"key":"762_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31188-0","volume":"395","author":"CS Goldsmith","year":"2020","unstructured":"Goldsmith, C. S., Miller, S. E., Martines, R. B., Bullock, H. A. & Zaki, S. R. Electron microscopy of SARS-CoV-2: a challenging task. Lancet 395, e99 (2020).","journal-title":"Lancet"},{"key":"762_CR35","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ajpath.2021.05.007","volume":"191","author":"RF Nicosia","year":"2021","unstructured":"Nicosia, R. F., Ligresti, G., Caporarello, N., Akilesh, S. & Ribatti, D. COVID-19 vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. Am. J. Pathol. 191, 1374\u20131384 (2021).","journal-title":"Am. J. Pathol."},{"key":"762_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"762_CR37","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1128\/JVI.01248-09","volume":"84","author":"I Glowacka","year":"2010","unstructured":"Glowacka, I. et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 84, 1198\u20131205 (2010).","journal-title":"J. Virol."},{"key":"762_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"H Wang","year":"2008","unstructured":"Wang, H. et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 18, 290\u2013301 (2008).","journal-title":"Cell Res."},{"key":"762_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"762_CR40","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1152\/ajplung.00498.2016","volume":"314","author":"CP Sodhi","year":"2018","unstructured":"Sodhi, C. P. et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin\/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L17\u2013L31 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"762_CR41","first-page":"1","volume":"44","author":"KD Bhoola","year":"1992","unstructured":"Bhoola, K. D., Figueroa, C. D. & Worthy, K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1\u201380 (1992).","journal-title":"Pharmacol. Rev."},{"key":"762_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.peptides.2018.05.007","volume":"105","author":"F Marceau","year":"2018","unstructured":"Marceau, F. et al. Bifunctional ligands of the bradykinin B2 and B1 receptors: an exercise in peptide hormone plasticity. Peptides 105, 37\u201350 (2018).","journal-title":"Peptides"},{"key":"762_CR43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57555","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk, F. L. et al. Kallikrein\u2013kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife https:\/\/doi.org\/10.7554\/eLife.57555 (2020).","journal-title":"eLife"},{"key":"762_CR44","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3389\/fimmu.2020.02014","volume":"11","author":"S Meini","year":"2020","unstructured":"Meini, S. et al. Understanding the pathophysiology of COVID-19: could the contact system be the key? Front. Immunol. 11, 2014 (2020).","journal-title":"Front. Immunol."},{"key":"762_CR45","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/jth.15509","volume":"19","author":"N Mackman","year":"2021","unstructured":"Mackman, N., Grover, S. P. & Antoniak, S. Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus. J. Thromb. Haemost. 19, 2652\u20132658 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR46","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/ATVBAHA.120.315547","volume":"41","author":"A Rosell","year":"2021","unstructured":"Rosell, A. et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler. Thromb. Vasc. Biol. 41, 878\u2013882 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"762_CR47","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/bloodadvances.2020003308","volume":"5","author":"C Guervilly","year":"2021","unstructured":"Guervilly, C. et al. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Adv. 5, 628\u2013634 (2021).","journal-title":"Blood Adv."},{"key":"762_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1126\/science.abm2052","volume":"375","author":"S Spudich","year":"2022","unstructured":"Spudich, S. & Nath, A. Nervous system consequences of COVID-19. Science 375, 267\u2013269 (2022).","journal-title":"Science"},{"key":"762_CR49","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"762_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMc2033369","volume":"384","author":"MH Lee","year":"2021","unstructured":"Lee, M. H. et al. Microvascular injury in the brains of patients with COVID-19. N. Engl. J. Med. 384, 481\u2013483 (2021).","journal-title":"N. Engl. J. Med."},{"key":"762_CR51","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41379-021-00793-y","volume":"34","author":"C Bryce","year":"2021","unstructured":"Bryce, C. et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod. Pathol. 34, 1456\u20131467 (2021).","journal-title":"Mod. Pathol."},{"key":"762_CR52","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1161\/STROKEAHA.120.030335","volume":"51","author":"S Yaghi","year":"2020","unstructured":"Yaghi, S. et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke 51, 2002\u20132011 (2020).","journal-title":"Stroke"},{"key":"762_CR53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","volume":"398","author":"I Katsoularis","year":"2021","unstructured":"Katsoularis, I., Fonseca-Rodriguez, O., Farrington, P., Lindmark, K. & Fors Connolly, A. M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 398, 599\u2013607 (2021).","journal-title":"Lancet"},{"key":"762_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1747493020972922","volume":"16","author":"S Nannoni","year":"2021","unstructured":"Nannoni, S., de Groot, R., Bell, S. & Markus, H. S. Stroke in COVID-19: a systematic review and meta-analysis. Int. J. Stroke 16, 137\u2013149 (2021).","journal-title":"Int. J. Stroke"},{"key":"762_CR55","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1212\/WNL.0000000000010979","volume":"96","author":"JA Frontera","year":"2021","unstructured":"Frontera, J. A. et al. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology 96, e575\u2013e586 (2021).","journal-title":"Neurology"},{"key":"762_CR56","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1741569","author":"E Shavit-Stein","year":"2022","unstructured":"Shavit-Stein, E. et al. Neurocoagulation from a mechanistic point of view in the central nervous system. Semin. Thromb. Hemost. https:\/\/doi.org\/10.1055\/s-0041-1741569 (2022).","journal-title":"Semin. Thromb. Hemost."},{"key":"762_CR57","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1161\/STROKEAHA.120.031971","volume":"52","author":"LS McAlpine","year":"2021","unstructured":"McAlpine, L. S. et al. Ischemic stroke, inflammation, and endotheliopathy in COVID-19 patients. Stroke 52, e233\u2013e238 (2021).","journal-title":"Stroke"},{"key":"762_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052681","author":"MA Erickson","year":"2021","unstructured":"Erickson, M. A., Rhea, E. M., Knopp, R. C. & Banks, W. A. Interactions of SARS-CoV-2 with the blood\u2013brain barrier. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22052681 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"762_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.15.21251511","author":"GE Serrano","year":"2021","unstructured":"Serrano, G. E. et al. Mapping of SARS-CoV-2 brain invasion and histopathology in COVID-19 disease. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.15.21251511 (2021).","journal-title":"medRxiv"},{"key":"762_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202135","author":"E Song","year":"2021","unstructured":"Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20202135 (2021).","journal-title":"J. Exp. Med."},{"key":"762_CR61","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41593-020-00771-8","volume":"24","author":"EM Rhea","year":"2021","unstructured":"Rhea, E. M. et al. The S1 protein of SARS-CoV-2 crosses the blood\u2013brain barrier in mice. Nat. Neurosci. 24, 368\u2013378 (2021).","journal-title":"Nat. Neurosci."},{"key":"762_CR62","doi-asserted-by":"publisher","first-page":"151682","DOI":"10.1016\/j.anndiagpath.2020.151682","volume":"51","author":"GJ Nuovo","year":"2021","unstructured":"Nuovo, G. J. et al. Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann. Diagn. Pathol. 51, 151682 (2021).","journal-title":"Ann. Diagn. Pathol."},{"key":"762_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbi.2021.12.007","volume":"100","author":"MG Frank","year":"2022","unstructured":"Frank, M. G. et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Brain Behav. Immun. 100, 267\u2013277 (2022).","journal-title":"Brain Behav. Immun."},{"key":"762_CR64","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41593-021-00926-1","volume":"24","author":"J Wenzel","year":"2021","unstructured":"Wenzel, J. et al. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat. Neurosci. 24, 1522\u20131533 (2021).","journal-title":"Nat. Neurosci."},{"key":"762_CR65","doi-asserted-by":"publisher","first-page":"600767","DOI":"10.3389\/fphys.2020.600767","volume":"11","author":"JM Ross","year":"2020","unstructured":"Ross, J. M. et al. The expanding cell diversity of the brain vasculature. Front. Physiol. 11, 600767 (2020).","journal-title":"Front. Physiol."},{"key":"762_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fimmu.2016.00311","volume":"7","author":"BN Porto","year":"2016","unstructured":"Porto, B. N. & Stein, R. T. Neutrophil extracellular traps in pulmonary diseases: too much of a good thing. Front. Immunol. 7, 311 (2016).","journal-title":"Front. Immunol."},{"key":"762_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138999","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.138999 (2020).","journal-title":"JCI Insight"},{"key":"762_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03482-z","volume":"25","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin\u2013neutrophil extracellular trap axis in neutrophils from COVID-19 patients. Crit. Care 25, 51 (2021).","journal-title":"Crit. Care"},{"key":"762_CR69","doi-asserted-by":"publisher","first-page":"205873842110480","DOI":"10.1177\/20587384211048026","volume":"35","author":"PE Marik","year":"2021","unstructured":"Marik, P. E., Iglesias, J., Varon, J. & Kory, P. A scoping review of the pathophysiology of COVID-19. Int. J. Immunopathol. Pharmacol. 35, 20587384211048026 (2021).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"762_CR70","doi-asserted-by":"publisher","first-page":"108598","DOI":"10.1016\/j.clim.2020.108598","volume":"220","author":"DC Mastellos","year":"2020","unstructured":"Mastellos, D. C. et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin. Immunol. 220, 108598 (2020).","journal-title":"Clin. Immunol."},{"key":"762_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.04.007","author":"C Magro","year":"2020","unstructured":"Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. https:\/\/doi.org\/10.1016\/j.trsl.2020.04.007 (2020).","journal-title":"Transl. Res."},{"key":"762_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-021-00725-2","author":"A Leatherdale","year":"2022","unstructured":"Leatherdale, A. et al. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality. Med. Microbiol. Immunol. https:\/\/doi.org\/10.1007\/s00430-021-00725-2 (2022).","journal-title":"Med. Microbiol. Immunol."},{"key":"762_CR73","doi-asserted-by":"publisher","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA 117, 25018\u201325025 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"762_CR74","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/infdis\/jiaa646","volume":"223","author":"AH de Nooijer","year":"2021","unstructured":"de Nooijer, A. H. et al. Complement activation in the disease course of COVID-19 and its effects on clinical outcomes. J. Infect. Dis. 223, 2214\u20132224 (2021).","journal-title":"J. Infect. Dis."},{"key":"762_CR75","doi-asserted-by":"publisher","first-page":"663187","DOI":"10.3389\/fimmu.2021.663187","volume":"12","author":"G Sinkovits","year":"2021","unstructured":"Sinkovits, G. et al. Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection. Front. Immunol. 12, 663187 (2021).","journal-title":"Front. Immunol."},{"key":"762_CR76","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1182\/blood.2020008248","volume":"136","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136, 2080\u20132089 (2020).","journal-title":"Blood"},{"key":"762_CR77","doi-asserted-by":"publisher","first-page":"714511","DOI":"10.3389\/fimmu.2021.714511","volume":"12","author":"YM Ali","year":"2021","unstructured":"Ali, Y. M. et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front. Immunol. 12, 714511 (2021).","journal-title":"Front. Immunol."},{"key":"762_CR78","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1111\/jth.15050","volume":"18","author":"EM Conway","year":"2020","unstructured":"Conway, E. M. & Pryzdial, E. L. Is the COVID-19 thrombotic catastrophe complement-connected? J. Thromb. Haemost. 18, 2812\u20132822 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR79","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-33390\/v1","author":"B Yan","year":"2020","unstructured":"Yan, B. et al. SARS-CoV2 drives JAK1\/2-dependent local and systemic complement hyper-activation. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-33390\/v1 (2020).","journal-title":"Res. Sq."},{"key":"762_CR80","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1111\/jth.12950","volume":"13","author":"EM Conway","year":"2015","unstructured":"Conway, E. M. Reincarnation of ancient links between coagulation and complement. J. Thromb. Haemost. 13, S121\u2013S132 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","volume":"2","author":"B Afzali","year":"2022","unstructured":"Afzali, B., Noris, M., Lambrecht, B. N. & Kemper, C. The state of complement in COVID-19. Nat. Rev. Immunol. 2, 77\u201384 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"762_CR82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11901-005-0030-4","volume":"4","author":"KI Schexneider","year":"2005","unstructured":"Schexneider, K. I. & Reedy, E. A. Thrombocytopenia in dengue fever. Curr. Hematol. Rep. 4, 145\u2013148 (2005).","journal-title":"Curr. Hematol. Rep."},{"key":"762_CR83","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1378\/chest.11-2860","volume":"141","author":"MT Rondina","year":"2012","unstructured":"Rondina, M. T. et al. In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest 141, 1490\u20131495 (2012).","journal-title":"Chest"},{"key":"762_CR84","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1182\/bloodadvances.2020001640","volume":"4","author":"AJG Jansen","year":"2020","unstructured":"Jansen, A. J. G. et al. Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. Blood Adv. 4, 2967\u20132978 (2020).","journal-title":"Blood Adv."},{"key":"762_CR85","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.thromres.2020.06.008","volume":"193","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb. Res. 193, 110\u2013115 (2020).","journal-title":"Thromb. Res."},{"key":"762_CR86","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jth.15566","volume":"20","author":"A Caillon","year":"2022","unstructured":"Caillon, A. et al. Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. J. Thromb. Haemost. 20, 17\u201331 (2022).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR87","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2020008762","volume":"137","author":"K Althaus","year":"2021","unstructured":"Althaus, K. et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 137, 1061\u20131071 (2021).","journal-title":"Blood"},{"key":"762_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317703","author":"Y Zaid","year":"2020","unstructured":"Zaid, Y. et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ. Res. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317703 (2020).","journal-title":"Circ. Res."},{"key":"762_CR89","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood.2020007214","volume":"136","author":"BK Manne","year":"2020","unstructured":"Manne, B. K. et al. Platelet gene expression and function in patients with COVID-19. Blood 136, 1317\u20131329 (2020).","journal-title":"Blood"},{"key":"762_CR90","doi-asserted-by":"publisher","first-page":"eabh2434","DOI":"10.1126\/sciadv.abh2434","volume":"7","author":"TJ Barrett","year":"2021","unstructured":"Barrett, T. J. et al. Platelets amplify endotheliopathy in COVID-19. Sci. Adv. 7, eabh2434 (2021).","journal-title":"Sci. Adv."},{"key":"762_CR91","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1161\/ATVBAHA.120.315175","volume":"40","author":"F Taus","year":"2020","unstructured":"Taus, F. et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler. Thromb. Vasc. Biol. 40, 2975\u20132989 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"762_CR92","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1055\/a-1347-5555","volume":"121","author":"V Leopold","year":"2021","unstructured":"Leopold, V. et al. Platelets are hyperactivated but show reduced glycoprotein VI reactivity in COVID-19 patients. Thromb. Haemost. 121, 1258\u20131262 (2021).","journal-title":"Thromb. Haemost."},{"key":"762_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-021-00899-1","volume":"11","author":"N Yatim","year":"2021","unstructured":"Yatim, N. et al. Platelet activation in critically ill COVID-19 patients. Ann. Intensive Care 11, 113 (2021).","journal-title":"Ann. Intensive Care"},{"key":"762_CR94","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2020007252","volume":"136","author":"ED Hottz","year":"2020","unstructured":"Hottz, E. D. et al. Platelet activation and platelet\u2013monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 136, 1330\u20131341 (2020).","journal-title":"Blood"},{"key":"762_CR95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201129","author":"FP Veras","year":"2020","unstructured":"Veras, F. P. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20201129 (2020).","journal-title":"J. Exp. Med."},{"key":"762_CR96","first-page":"1454","volume":"14","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Zhou, L., Kou, Y. & Kou, J. Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19. Am. J. Transl. Res. 14, 1454\u20131468 (2022).","journal-title":"Am. J. Transl. Res."},{"key":"762_CR97","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/CIRCRESAHA.120.317803","volume":"127","author":"TJ Barrett","year":"2020","unstructured":"Barrett, T. J. et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ. Res. 127, 945\u2013947 (2020).","journal-title":"Circ. Res."},{"key":"762_CR98","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood.2019000200","volume":"134","author":"P Davizon-Castillo","year":"2019","unstructured":"Davizon-Castillo, P. et al. TNF-\u03b1-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood 134, 727\u2013740 (2019).","journal-title":"Blood"},{"key":"762_CR99","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/ATVBAHA.120.315186","volume":"41","author":"M Ezzaty Mirhashemi","year":"2021","unstructured":"Ezzaty Mirhashemi, M. et al. The dynamic platelet transcriptome in obesity and weight loss. Arterioscler. Thromb. Vasc. Biol. 41, 854\u2013864 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"762_CR100","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3109\/09537104.2015.1083543","volume":"27","author":"JD Eicher","year":"2016","unstructured":"Eicher, J. D. et al. Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction. Platelets 27, 230\u2013239 (2016).","journal-title":"Platelets"},{"key":"762_CR101","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/jth.15534","volume":"19","author":"TJ Barrett","year":"2021","unstructured":"Barrett, T. J. et al. Platelets contribute to disease severity in COVID-19. J. Thromb. Haemost. 19, 3139\u20133153 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR102","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/CIRCRESAHA.121.319117","volume":"129","author":"M Koupenova","year":"2021","unstructured":"Koupenova, M. et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ. Res. 129, 631\u2013646 (2021).","journal-title":"Circ. Res."},{"key":"762_CR103","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2018-09-873984","volume":"133","author":"RA Campbell","year":"2019","unstructured":"Campbell, R. A. et al. Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood 133, 2013\u20132026 (2019).","journal-title":"Blood"},{"key":"762_CR104","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","volume":"399","author":"RC Group","year":"2022","unstructured":"Group, R. C. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 143\u2013151 (2022).","journal-title":"Lancet"},{"key":"762_CR105","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jama.2021.23605","volume":"327","author":"JS Berger","year":"2022","unstructured":"Berger, J. S. et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA 327, 227\u2013236 (2022).","journal-title":"JAMA"},{"key":"762_CR106","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jth.15016","volume":"18","author":"C Nougier","year":"2020","unstructured":"Nougier, C. et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J. Thromb. Haemost. 18, 2215\u20132219 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR107","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1111\/jth.15043","volume":"18","author":"A Blasi","year":"2020","unstructured":"Blasi, A. et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J. Thromb. Haemost. 18, 2646\u20132653 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113487","author":"M Ranucci","year":"2020","unstructured":"Ranucci, M. et al. COVID-19-associated coagulopathy: biomarkers of thrombin generation and fibrinolysis leading the outcome. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9113487 (2020).","journal-title":"J. Clin. Med."},{"key":"762_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85906-y","volume":"11","author":"ME de la Morena-Barrio","year":"2021","unstructured":"de la Morena-Barrio, M. E. et al. Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Sci. Rep. 11, 7792 (2021).","journal-title":"Sci. Rep."},{"key":"762_CR110","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64330","author":"AE Mast","year":"2021","unstructured":"Mast, A. E. et al. SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. eLife https:\/\/doi.org\/10.7554\/eLife.64330 (2021).","journal-title":"eLife"},{"key":"762_CR111","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1165\/rcmb.2020-0453OC","volume":"64","author":"ES FitzGerald","year":"2021","unstructured":"FitzGerald, E. S., Chen, Y., Fitzgerald, K. A. & Jamieson, A. M. Lung epithelial cell transcriptional regulation as a factor in COVID-19-associated coagulopathies. Am. J. Respir. Cell Mol. Biol. 64, 687\u2013697 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"762_CR112","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00271-13","author":"LE Gralinski","year":"2013","unstructured":"Gralinski, L. E. et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio https:\/\/doi.org\/10.1128\/mBio.00271-13 (2013).","journal-title":"mBio"},{"key":"762_CR113","first-page":"4348","volume":"130","author":"Z Zheng","year":"2020","unstructured":"Zheng, Z. et al. Interacting hepatic PAI-1\/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. J. Clin. Invest. 130, 4348\u20134359 (2020).","journal-title":"J. Clin. Invest."},{"key":"762_CR114","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/rth2.12362","volume":"4","author":"JH Griffin","year":"2020","unstructured":"Griffin, J. H. & Lyden, P. COVID-19 hypothesis: activated protein C for therapy of virus-induced pathologic thromboinflammation. Res. Pract. Thromb. Haemost. 4, 506\u2013509 (2020).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"762_CR115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2018-02-769026","volume":"132","author":"JH Griffin","year":"2018","unstructured":"Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132, 159\u2013169 (2018).","journal-title":"Blood"},{"key":"762_CR116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2021.05.016","volume":"204","author":"TM Stanne","year":"2021","unstructured":"Stanne, T. M., Pedersen, A., Gisslen, M. & Jern, C. Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19. Thromb. Res. 204, 13\u201315 (2021).","journal-title":"Thromb. Res."},{"key":"762_CR117","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1111\/jth.14973","volume":"18","author":"NL Jackson Chornenki","year":"2020","unstructured":"Jackson Chornenki, N. L. et al. Identification of hemostatic markers that define the pre-DIC state: a multi-center observational study. J. Thromb. Haemost. 18, 2524\u20132531 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR118","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1378\/chest.120.3.915","volume":"120","author":"SB Yan","year":"2001","unstructured":"Yan, S. B., Helterbrand, J. D., Hartman, D. L., Wright, T. J. & Bernard, G. R. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120, 915\u2013922 (2001).","journal-title":"Chest"},{"key":"762_CR119","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/j.1538-7836.2009.03577.x","volume":"7","author":"AR Folsom","year":"2009","unstructured":"Folsom, A. R., Ohira, T., Yamagishi, K. & Cushman, M. Low protein C and incidence of ischemic stroke and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. J. Thromb. Haemost. 7, 1774\u20131778 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR120","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000516287","volume":"55","author":"A Tin","year":"2021","unstructured":"Tin, A. et al. Association between circulating protein C levels and incident dementia: the atherosclerosis risk in communities study. Neuroepidemiology 55, 306\u2013315 (2021).","journal-title":"Neuroepidemiology"},{"key":"762_CR121","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/jth.15327","volume":"19","author":"GK Juneja","year":"2021","unstructured":"Juneja, G. K. et al. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: a single-center prospective longitudinal study. J. Thromb. Haemost. 19, 1546\u20131557 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR122","doi-asserted-by":"publisher","first-page":"101069","DOI":"10.1016\/j.eclinm.2021.101069","volume":"39","author":"IMB Francischetti","year":"2021","unstructured":"Francischetti, I. M. B. et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine 39, 101069 (2021).","journal-title":"EClinicalMedicine"},{"key":"762_CR123","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/MBC.0000000000001070","volume":"32","author":"N Bayrakci","year":"2021","unstructured":"Bayrakci, N. et al. Relationship between serum soluble endothelial protein C receptor level and COVID-19 findings. Blood Coagul. Fibrinolysis 32, 550\u2013555 (2021).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"762_CR124","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","volume":"44","author":"JS Knight","year":"2022","unstructured":"Knight, J. S. & Kanthi, Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin. Immunopathol. 44, 347\u2013362 (2022).","journal-title":"Semin. Immunopathol."},{"key":"762_CR125","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11926-021-01041-7","volume":"23","author":"M Stelzer","year":"2021","unstructured":"Stelzer, M., Henes, J. & Saur, S. The role of antiphospholipid antibodies in COVID-19. Curr. Rheumatol. Rep. 23, 72 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"762_CR126","doi-asserted-by":"publisher","first-page":"103012","DOI":"10.1016\/j.autrev.2021.103012","volume":"21","author":"J Damoiseaux","year":"2022","unstructured":"Damoiseaux, J. et al. Autoantibodies and SARS-CoV2 infection: the spectrum from association to clinical implication: report of the 15th Dresden Symposium on Autoantibodies. Autoimmun. Rev. 21, 103012 (2022).","journal-title":"Autoimmun. Rev."},{"key":"762_CR127","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3876","author":"Y Zuo","year":"2020","unstructured":"Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd3876 (2020).","journal-title":"Sci. Transl. Med."},{"key":"762_CR128","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/jth.15455","volume":"19","author":"A Hollerbach","year":"2021","unstructured":"Hollerbach, A. et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J. Thromb. Haemost. 19, 2335\u20132347 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR129","doi-asserted-by":"publisher","DOI":"10.1002\/art.42094","author":"H Shi","year":"2022","unstructured":"Shi, H. et al. Endothelial cell-activating antibodies in COVID-19. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42094 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"762_CR130","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Munoz-Fontela","year":"2020","unstructured":"Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"762_CR131","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon III","year":"2020","unstructured":"Dinnon, K. H. III et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020).","journal-title":"Nature"},{"key":"762_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001284","volume":"19","author":"A Muruato","year":"2021","unstructured":"Muruato, A. et al. Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biol. 19, e3001284 (2021).","journal-title":"PLoS Biol."},{"key":"762_CR133","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085.e12 (2020).","journal-title":"Cell"},{"key":"762_CR134","doi-asserted-by":"publisher","first-page":"103381","DOI":"10.1016\/j.ebiom.2021.103381","volume":"67","author":"K Huang","year":"2021","unstructured":"Huang, K. et al. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine 67, 103381 (2021).","journal-title":"EBioMedicine"},{"key":"762_CR135","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.15.480515","author":"KH Dinnon","year":"2022","unstructured":"Dinnon, K. H. et al. A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.02.15.480515 (2022).","journal-title":"bioRxiv"},{"key":"762_CR136","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr","year":"2007","unstructured":"McCray, P. B. Jr et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"762_CR137","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"762_CR138","doi-asserted-by":"publisher","DOI":"10.1177\/03009858211066841","author":"E Vidal","year":"2021","unstructured":"Vidal, E. et al. Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice. Vet. Pathol. https:\/\/doi.org\/10.1177\/03009858211066841 (2021).","journal-title":"Vet. Pathol."},{"key":"762_CR139","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"762_CR140","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"762_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/v13122506","author":"JR Port","year":"2021","unstructured":"Port, J. R. et al. High-fat high-sugar diet-induced changes in the lipid metabolism are associated with mildly increased COVID-19 severity and delayed recovery in the Syrian hamster. Viruses https:\/\/doi.org\/10.3390\/v13122506 (2021).","journal-title":"Viruses"},{"key":"762_CR142","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"762_CR143","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","volume":"7","author":"Y Fan","year":"2022","unstructured":"Fan, Y. et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal. Transduct. Target. Ther. 7, 141 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"762_CR144","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12985-020-01396-w","volume":"17","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. Virol. J. 17, 125 (2020).","journal-title":"Virol. J."},{"key":"762_CR145","doi-asserted-by":"publisher","DOI":"10.1177\/03009858211067468","author":"CS Clancy","year":"2021","unstructured":"Clancy, C. S. et al. Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: an institutional comparative review. Vet. Pathol. https:\/\/doi.org\/10.1177\/03009858211067468 (2021).","journal-title":"Vet. Pathol."},{"key":"762_CR146","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41590-020-00835-8","volume":"22","author":"C Woolsey","year":"2021","unstructured":"Woolsey, C. et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat. Immunol. 22, 86\u201398 (2021).","journal-title":"Nat. Immunol."},{"key":"762_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95512-7","volume":"11","author":"CA Gomez","year":"2021","unstructured":"Gomez, C. A. et al. Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis. Sci. Rep. 11, 16025 (2021).","journal-title":"Sci. Rep."},{"key":"762_CR148","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1111\/jth.15490","volume":"19","author":"H Fogarty","year":"2021","unstructured":"Fogarty, H. et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 19, 2546\u20132553 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"762_CR149","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-021-01359-7","volume":"20","author":"E Pretorius","year":"2021","unstructured":"Pretorius, E. et al. Persistent clotting protein pathology in long COVID\/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 20, 172 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"762_CR150","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1744302","author":"JG Rizk","year":"2022","unstructured":"Rizk, J. G. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin. Thromb. Hemost. https:\/\/doi.org\/10.1055\/s-0042-1744302 (2022).","journal-title":"Semin. Thromb. Hemost."},{"key":"762_CR151","doi-asserted-by":"publisher","DOI":"10.1159\/000522498","author":"T Alnima","year":"2022","unstructured":"Alnima, T., Mulder, M. M. G., van Bussel, B. C. T. & Ten Cate, H. COVID-19 coagulopathy: from pathogenesis to treatment. Acta Haematol. https:\/\/doi.org\/10.1159\/000522498 (2022).","journal-title":"Acta Haematol."},{"key":"762_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069590","volume":"377","author":"I Katsoularis","year":"2022","unstructured":"Katsoularis, I. et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study. BMJ 377, e069590 (2022).","journal-title":"BMJ"},{"key":"762_CR153","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39\u201350 (2022).","journal-title":"Nat. Med."},{"key":"762_CR154","unstructured":"American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. American Society of Hematology https:\/\/www.hematology.org\/education\/clinicians\/guidelines-and-quality-care\/clinical-practice-guidelines\/venous-thromboembolism-guidelines\/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19 (2022)."},{"key":"762_CR155","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health https:\/\/www.covid19treatmentguidelines.nih.gov\/ (2022)."},{"key":"762_CR156","unstructured":"BC Centre for Disease Control. Antimicrobial and immunomodulatory therapy in adult patients with COVID-19. BC Centre for Disease Control http:\/\/www.bccdc.ca\/health-professionals\/clinical-resources\/covid-19-care\/treatments (2022)."},{"key":"762_CR157","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s42399-022-01121-4","volume":"4","author":"BL Thoms","year":"2022","unstructured":"Thoms, B. L., Gosselin, J., Libman, B., Littenberg, B. & Budd, R. C. Efficacy of combination therapy with the JAK inhibitor baricitinib in the treatment of COVID-19. SN Compr. Clin. Med. 4, 42 (2022).","journal-title":"SN Compr. Clin. Med."},{"key":"762_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020241","author":"W Hafez","year":"2022","unstructured":"Hafez, W. et al. Treatment outcomes of tocilizumab in critically-ill COVID-19 patients, single-centre retrospective study. Antibiotics https:\/\/doi.org\/10.3390\/antibiotics11020241 (2022).","journal-title":"Antibiotics"},{"key":"762_CR159","first-page":"CD013739","volume":"3","author":"RL Flumignan","year":"2022","unstructured":"Flumignan, R. L. et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst. Rev. 3, CD013739 (2022).","journal-title":"Cochrane Database Syst. Rev."},{"key":"762_CR160","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S2213-2600(21)00455-0","volume":"10","author":"JL Vincent","year":"2022","unstructured":"Vincent, J. L., Levi, M. & Hunt, B. J. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir. Med. 10, 214\u2013220 (2022).","journal-title":"Lancet Respir. Med."},{"key":"762_CR161","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3890","volume":"5","author":"JH Chow","year":"2022","unstructured":"Chow, J. H. et al. Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19. JAMA Netw. Open 5, e223890 (2022).","journal-title":"JAMA Netw. Open"},{"key":"762_CR162","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2910","author":"REMAP-CAP Writing Committee for the REMAP-CAP Investigators.","year":"2022","unstructured":"REMAP-CAP Writing Committee for the REMAP-CAP Investigators. et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA https:\/\/doi.org\/10.1001\/jama.2022.2910 (2022).","journal-title":"JAMA"},{"key":"762_CR163","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.chest.2021.09.024","volume":"161","author":"CD Barrett","year":"2022","unstructured":"Barrett, C. D. et al. Study of alteplase for respiratory failure in SARS-CoV-2 COVID-19: a vanguard multicenter, rapidly adaptive, pragmatic, randomized controlled trial. Chest 161, 710\u2013727 (2022).","journal-title":"Chest"},{"key":"762_CR164","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00210-022-02206-6","volume":"395","author":"MF da Silva","year":"2022","unstructured":"da Silva, M. F. et al. Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives. Naunyn Schmiedebergs Arch. Pharmacol. 395, 275\u2013283 (2022).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"762_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04884-0","volume":"21","author":"J Declercq","year":"2020","unstructured":"Declercq, J. et al. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): a structured summary of a study protocol for a randomised controlled trial. Trials 21, 934 (2020).","journal-title":"Trials"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00762-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T16:51:13Z","timestamp":1727715073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-022-00762-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":165,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1038\/s41577-022-00762-9","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"4 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}